Powder: -20°C for 3 years | In solvent: -80°C for 1 year
SCR7 是一种特异性 DNA 连接酶 IV 抑制剂,可阻断非同源末端连接。它是一种不稳定的形式,可以自动循环成稳定形式的 SCR7 pyrazine。它也是CRISPR/Cas9的增强子,可提高 Cas9 介导的同源性定向修复的效率。它诱导细胞凋亡并具有抗癌活性。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 560 | 35日内发货 | ||
5 mg | ¥ 1,900 | 35日内发货 | ||
10 mg | ¥ 3,220 | 35日内发货 | ||
25 mg | ¥ 5,880 | 35日内发货 |
SCR7 的其他形式现货产品:
产品描述 | SCR7, a specific DNA Ligase IV inhibitor, blocks nonhomologous end-joining (NHEJ). |
体外活性 | 在负荷Dalton's淋巴瘤的Swiss albino小鼠模型中,腹腔注射SCR7(20 mg/kg)不能够消退肿瘤.在BALB/c小鼠体内,腹腔注射SCR7(20 mg/kg)能够增强辐射,依托泊苷和3-氨基苯甲酰胺对于Dalton's淋巴瘤细胞的衍生瘤的细胞毒性作用. |
体内活性 | 在MCF7细胞(IC50=40 μM),A549细胞(IC50=34 μM),HeLa细胞(IC50=44 μM),T47D细胞(IC50=8.5 μM),A2780细胞(IC50=120 μM),HT1080细胞(IC50=10 μM),和Nalm6细胞(IC50=50 μM)中,SCR7能够显著抑制细胞增殖。 |
激酶实验 | Complementation of SCR7 Inhibition with Puri?ed Ligase IV: Complementation experiment is carried out by adding increasing concentrations of puri?ed Ligase IV/XRCC4 complex (30, 60, and 120 fmol) along with the oligomeric DNA substrates (5' compatible and 5'-5' noncompatible ends) to the SCR7-treatedextracts. Reactions are incubated for 2 h at 25℃. The reaction products are then resolved on 8% denaturing PAGE. The gel is dried and exposed and the signal is detected with a PhosphorImager and analyzed with Multi Gauge (V3.0) software. |
细胞实验 | SCR7 is dissolved in DMSO and stored, and then diluted with appropriate medium before use[3]. Wild-type, AAVS1TLR HEK293 and mouse NIH3T3 cells are maintained in DMEM supplied with 15% FBS, cells are passaged three times per week. The mouse Burkitt lymphoma cell line, generated from a Burkitt-like mouse lymphoma is maintained in DMEM supplied with 15% FBS, 2 mM HEPES, 2 mM sodium pyruvate, 2 mM L-glutamine, and 1× NAA, beta-mercaptoethanol and passaged four times per week. For puromycin selection, mCherry+ cells are sorted, seeded at 103 cells/well and selected with 3 mg/mL of Puromycin for 2 weeks. Then colonies are counted and single cells are sorted. The SCR7 inhibitor is purchased, 12 h after transfection these cells are maintained in complete medium supplied with 1 mM SCR7 inhibitor until analysis. At SCR7 concentrations of 60 mM and 10 mM, A reduction of transfection efficiency and of cell viability is observed[3]. |
分子量 | 334.4 |
分子式 | C18H14N4OS |
CAS No. | 1533426-72-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 45 mg/mL (134.57 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.9904 mL | 14.9522 mL | 29.9043 mL | 74.7608 mL |
5 mM | 0.5981 mL | 2.9904 mL | 5.9809 mL | 14.9522 mL | |
10 mM | 0.299 mL | 1.4952 mL | 2.9904 mL | 7.4761 mL | |
20 mM | 0.1495 mL | 0.7476 mL | 1.4952 mL | 3.738 mL | |
50 mM | 0.0598 mL | 0.299 mL | 0.5981 mL | 1.4952 mL | |
100 mM | 0.0299 mL | 0.1495 mL | 0.299 mL | 0.7476 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
SCR7 1533426-72-0 Apoptosis Cell Cycle/Checkpoint DNA Damage/DNA Repair DNA/RNA Synthesis CRISPR/Cas9 gene end-joining nonhomologous SCR 7 Caspase 9 phosphorylation Caspase 3 ligase-IV SCR-7 inhibit replacement Inhibitor DNA anticancer inhibitor